Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial
- 47 Downloads
Contrast-induced nephropathy (CIN) is one of the most important complications of contrast media. We aimed to evaluate the preventive effects of pentoxifylline (PTX) on CIN in diabetic patients undergoing angioplasty using cystatin C.
Materials and methods
The present study was a randomized clinical trial, which was investigated the impact of PTX in the prevention of CIN among 90 diabetic patients undergoing the angioplasty using cystatin C as a novel biomarker of renal injury. The patients randomly were allocated 1:1 into the intervention and the control groups. The intervention group received a total of 1200 mg PTX orally before the angioplasty. The serum level of cystatin C and creatinine was measured at baseline and 24 h after the procedure.
The incidence of CIN was 8.9% in the PTX group vs. 6.7% in the control group (p = 1.00). The baseline level of cystatin C was 1.31 ± 0.39 mg/L in the PTX group and 1.24 ± 0.42 mg/L in the control group (p = 0.561). After angioplasty, the level of cystatin C was increased to 1.33 ± 0.61 in PTX group and to 1.31 ± 0.47 in the control group but was not statistically significant. The similar pattern was also seen in the level of serum creatinine.
The results of this study did not support the potential benefit of PTX in the prevention of CIN in diabetic patients undergoing angioplasty.
KeywordsAngioplasty Contrast-induced nephropathy (CIN) Pentoxifylline Diabetes
The authors would like to thank the Cardiovascular Research Center of Shahid Madani, Tabriz University of Medical Sciences (Tabriz, Iran), for support of the investigation.
This study was granted by the Cardiovascular Research Center of Shahid Madani, Tabriz University of Medical Sciences (Tabriz, Iran).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Müller R, Lebrach F (1979) Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica 2(6):372–379Google Scholar
- 6.Dauber IM, Lesnefsky EJ, Ashmore RC et al (1992) Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J Pharmacol Exp Ther 260(3):1250–1256Google Scholar
- 8.Freitas JP, Filipe P, Guerra-Rodrigo F (1995) Potential antioxidative effects of pentoxifylline. CRSeances Soc Biol Fil 189(3):401–405Google Scholar
- 15.Lechleitner P, Genser N, Mair J et al (1992) Pentoxifylline influences acute-phase response in acute myocardial infarction. J Mol Med 70(9):755Google Scholar
- 18.World Medical Association Declaration of Helsinki (2013) Ethical principles for medical research involving human subjects. World Medical Association. JAMA 310:2191–2194Google Scholar
- 19.Rahman MM, Haque HS, Banerjee SK, Ahsan SA, Rahman MF, Mahmood M, Salman M, Azam MG (2010) Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty. Mymensingh Med J 19:372–376Google Scholar
- 24.Bachorzewska-Gajewska H, Malyszko J, Sitniewska E et al (2008) NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol 127(2):290–291CrossRefGoogle Scholar